Mylod%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at

## Overview Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at is a brand name for **triflusal**. It is an antiplatelet agent. ## Primary Indications * Prevention of atherothrombotic events (e.g., myocardial infarction, stroke) in patients with established cardiovascular disease. * Adjunctive therapy in patients undergoing coronary artery bypass graft (CABG) surgery. ## Adult Dosing * **Prevention of atherothrombotic events:** 300 mg orally once daily. * **Adjunctive therapy in CABG surgery:** 300 mg orally once daily, starting at least 5 days before surgery and continuing for 1 month post-operatively. ## Pediatric Dosing No established pediatric dosing. ## Dose Adjustments * **Renal Impairment:** Use with caution in severe renal impairment; dose reduction may be considered based on clinical judgment and local protocols. * **Hepatic Impairment:** Use with caution in hepatic impairment; dose reduction may be considered based on clinical judgment and local protocols. ## Contraindications * Hypersensitivity to triflusal or any component of the formulation. * Active bleeding (e.g., gastrointestinal bleeding, intracranial hemorrhage). * Patients with a history of bronchospasm or allergic reactions to aspirin or other NSAIDs. ## Adverse Effects * **Common:** Gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain), dyspepsia, headache, dizziness. * **Serious:** Bleeding (including gastrointestinal hemorrhage, epistaxis, hematuria), hypersensitivity reactions (including bronchospasm, rash, urticaria), tinnitus, hearing loss. ## Key Drug Interactions * **Anticoagulants (e.g., warfarin, heparin):** Increased risk of bleeding. Monitor INR closely and adjust anticoagulant dose as needed. * **Other Antiplatelet Agents (e.g., aspirin, clopidogrel):** Increased risk of bleeding. Avoid concomitant use unless clinically indicated and with close monitoring. * **NSAIDs:** Increased risk of gastrointestinal bleeding and impaired renal function. * **Methotrexate:** Triflusal can increase methotrexate levels, potentially leading to toxicity. Avoid concomitant use or monitor closely. * **Oral Hypoglycemics:** Triflusal may potentiate the hypoglycemic effect. Monitor blood glucose closely. ## Monitoring * Signs and symptoms of bleeding (e.g., bruising, hematuria, melena, epistaxis). * Renal and hepatic function periodically. * Platelet aggregation studies may be considered in specific situations. ## Clinical Pearls * Triflusal has a longer half-life than aspirin and is generally associated with a lower incidence of gastrointestinal side effects compared to aspirin. * It is a prodrug that is rapidly metabolized to its active metabolite, 2-hydroxy-triflusal. * Discontinuation of triflusal may be necessary several days before elective surgery to minimize bleeding risk; consult surgical protocols. *** This information is for educational purposes only and does not substitute for professional medical advice. Always verify current prescribing information with the official drug manufacturer's package insert or consult with a qualified healthcare provider.